Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The Platelet Lifeline to Cancer: Challenges and Opportunities.

Literature DB >> 29657130

The Platelet Lifeline to Cancer: Challenges and Opportunities.

Monika Haemmerle¹, Rebecca L Stone², David G Menter³, Vahid Afshar-Kharghan⁴, Anil K Sood⁵.

Abstract

Besides their function in limiting blood loss and promoting wound healing, experimental evidence has highlighted platelets as active players in all steps of tumorigenesis including tumor growth, tumor cell extravasation, and metastasis. Additionally, thrombocytosis in cancer patients is associated with adverse patient survival. Due to the secretion of large amounts of microparticles and exosomes, platelets are well positioned to coordinate both local and distant tumor-host crosstalk. Here, we present a review of recent discoveries in the field of platelet biology and the role of platelets in cancer progression as well as challenges in targeting platelets for cancer treatment.

Entities: CellLine Chemical Disease Gene Species

Keywords: anti-platelet therapy; aspirin; biomarker; cancer; cancer therapy; metastasis; microparticles; platelets; thrombocytosis; tumor angiogenesis

Mesh：

Year: 2018 PMID： 29657130 PMCID： PMC5997503 DOI： 10.1016/j.ccell.2018.03.002

Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743

181 in total

1. Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease.

Authors: Paul A Gurbel; Kevin P Bliden; Susan E Turner; Udaya S Tantry; Martin G Gesheff; Travis P Barr; Lidija Covic; Athan Kuliopulos
Journal: Arterioscler Thromb Vasc Biol Date: 2016-01 Impact factor: 8.311

Review 2. Current state and novel approaches of antiplatelet therapy.

Authors: Pat Metharom; Michael C Berndt; Ross I Baker; Robert K Andrews
Journal: Arterioscler Thromb Vasc Biol Date: 2015-04-02 Impact factor: 8.311

3. Shedding of procoagulant microparticles from unstimulated platelets by integrin-mediated destabilization of actin cytoskeleton.

Authors: Sandra Cauwenberghs; Marion A H Feijge; Alan G S Harper; Stewart O Sage; Joyce Curvers; Johan W M Heemskerk
Journal: FEBS Lett Date: 2006-09-12 Impact factor: 4.124

4. Platelet-derived microparticles bind to hematopoietic stem/progenitor cells and enhance their engraftment.

Authors: A Janowska-Wieczorek; M Majka; J Kijowski; M Baj-Krzyworzeka; R Reca; A R Turner; J Ratajczak; S G Emerson; M A Kowalska; M Z Ratajczak
Journal: Blood Date: 2001-11-15 Impact factor: 22.113

5. Platelet integrin α6β1 controls lung metastasis through direct binding to cancer cell-derived ADAM9.

Authors: Elmina Mammadova-Bach; Paola Zigrino; Camille Brucker; Catherine Bourdon; Monique Freund; Adèle De Arcangelis; Scott I Abrams; Gertaud Orend; Christian Gachet; Pierre Henri Mangin
Journal: JCI Insight Date: 2016-09-08

6. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis.

Authors: P Prandoni; A W Lensing; H R Büller; M Carta; A Cogo; M Vigo; D Casara; A Ruol; J W ten Cate
Journal: Lancet Date: 1992-02-22 Impact factor: 79.321

7. The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets.

Authors: Nadia M Bambace; Jamie E Levis; Chris E Holmes
Journal: Platelets Date: 2010 Impact factor: 3.862

8. Anticoagulation inhibits tumor cell-mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response.

Authors: Elisabeth M Battinelli; Beth A Markens; Rajesh A Kulenthirarajan; Kellie R Machlus; Robert Flaumenhaft; Joseph E Italiano
Journal: Blood Date: 2013-09-24 Impact factor: 22.113

9. Decreased platelet reactivity in patients with cancer is associated with high risk of venous thromboembolism and poor prognosis.

Authors: Julia Riedl; Alexandra Kaider; Christine Marosi; Gerald W Prager; Beate Eichelberger; Alice Assinger; Ingrid Pabinger; Simon Panzer; Cihan Ay
Journal: Thromb Haemost Date: 2016-10-20 Impact factor: 5.249

10. Platelet P2Y12 is involved in murine pulmonary metastasis.

Authors: Yanhua Wang; Yueping Sun; Ding Li; Lin Zhang; Kemin Wang; Yong Zuo; T Kent Gartner; Junling Liu
Journal: PLoS One Date: 2013-11-13 Impact factor: 3.240

131 in total

1. A three-platelet mRNA set: MAX, MTURN and HLA-B as biomarker for lung cancer.

Authors: Lele Liu; Xingguo Song; Xinyi Li; Linlin Xue; Shanshan Ding; Limin Niu; Li Xie; Xianrang Song
Journal: J Cancer Res Clin Oncol Date: 2019-09-24 Impact factor: 4.553

2. Novel Mouse Model for Studying Hemostatic Function of Human Platelets.

Authors: David S Paul; Wolfgang Bergmeier
Journal: Arterioscler Thromb Vasc Biol Date: 2020-06-04 Impact factor: 8.311

3. Analysis of circulating breast cancer cell heterogeneity and interactions with peripheral blood mononuclear cells.

Authors: Heather M Brechbuhl; Kiran Vinod-Paul; Austin E Gillen; Etana G Kopin; Kari Gibney; Anthony D Elias; Masanori Hayashi; Carol A Sartorius; Peter Kabos
Journal: Mol Carcinog Date: 2020-08-21 Impact factor: 4.784

4. Perfluorocarbon nanoparticle-mediated platelet inhibition promotes intratumoral infiltration of T cells and boosts immunotherapy.

Authors: Zaigang Zhou; Baoli Zhang; Wenjing Zai; Lin Kang; Ahu Yuan; Yiqiao Hu; Jinhui Wu
Journal: Proc Natl Acad Sci U S A Date: 2019-05-29 Impact factor: 11.205

10. Platelet deficiency in Tpo^-/- mice can both promote and suppress the metastasis of experimental breast tumors in an organ-specific manner.

Authors: Wilko Thiele; Melanie Rothley; Arno Dimmler; Peter Bugert; Carla Salomó Coll; Jonathan P Sleeman
Journal: Clin Exp Metastasis Date: 2018-07-24 Impact factor: 5.150